Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Donostia / San Sebastian – page 14

210 clinical trials in Donostia / San Sebastian, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Donostia / San Sebastian at a glance
210
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

210 trials in Donostia / San Sebastian

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Medica Scientia Innovation Research S.L.

Uveitis

Not recruiting

Study on Methotrexate and Adalimumab for Non-Infectious Uveitis in Patients: Evaluating Effectiveness and Safety

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Dementia Alzheimer's type

Not recruiting

Study on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mirodenafil Dihydrochloride
  • Sponsor:Aribio Co. Ltd.

Splenic marginal zone lymphoma

Not recruiting

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Richter's syndrome

Not recruiting

Study of Mosunetuzumab and Drug Combination for Untreated Patients with Richter's Syndrome

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:Grupo Espanol De Leucemia Linfocitica Cronica

Bacterial infection

Not recruiting

Study Comparing 7-Day and 14-Day Treatment with Vancomycin, Linezolid, and Daptomycin for Patients with Uncomplicated Enterococcal Blood Infections

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Soft tissue sarcoma

Not recruiting

Study on the Effectiveness and Safety of L19TNF and Dacarbazine for Patients with Advanced or Metastatic Soft-Tissue Sarcoma After Previous Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Philogen S.p.A.

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effectiveness and Safety of Nipocalimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Ovarian cancer

Not recruiting

Study on Niraparib for Maintenance Treatment in Patients with Advanced Ovarian Cancer After Initial Chemotherapy Response

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Tesaro Inc.

HER2 positive breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Medica Scientia Innovation Research S.L.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Donostia / San Sebastian

What the registry says about research in the country

01 Neurodegenerative Diseases

Groundbreaking research focusing on Parkinson's disease and Alzheimer's disease, including studies of novel therapeutics and disease-modifying treatments.

  • LRRK2-driven Parkinson's treatment evaluation
  • Early-stage Alzheimer's interventions
  • Down syndrome-associated Alzheimer's research

Multiple trials investigating innovative approaches to manage disease progression and symptoms.

02 Oncology Studies

Comprehensive research into various cancer types, with emphasis on advanced colorectal cancer and melanoma treatments.

  • Targeted therapies for pancreatic adenocarcinoma
  • Brain metastases in melanoma patients
  • Innovative combinations for lymphomas

Focus on personalized treatment approaches and novel drug combinations.

03 Rare Diseases

Specialized research targeting Amyotrophic Lateral Sclerosis (ALS) and other rare conditions, exploring innovative therapeutic approaches.

  • Combined therapy approaches for ALS
  • Soft tissue sarcoma treatments
  • Ocular Myasthenia Gravis studies

Development of targeted therapies for challenging medical conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.